Are inflammatory bowel disease and/or treatment with aminosalicylates protective factors against Parkinson’s disease?
Objective: To analyze the association between aminosalicylate-treated inflammatory bowel disease (IBD-A) and Parkinson´s disease (PD) at population level. Background: According to the dual-hit hypothesis, the…Differences of gut bacterial community relate to pathology progress in Parkinson’s disease
Objective: The aim of this study is to examine whether intestinal microbiota correlate with progression of clinical severity and serum inflammation marker. Background: Constipation is…Is tremor related to celiac disease?
Objective: To evaluate the prevalence and clinical correlates of tremor in CD. Background: Celiac disease (CD) is a systemic autoimmune disease, whose prevalence is of…Reliability of a newly developed protocol for fiberoptic endoscopic evaluation of swallowing in Parkinson’s patients (PARK-FEES)
Objective: A new FEES protocol specified for dysphagia diagnosis among Parkinson's disease (PD) patients was recently developed in a prior two-phased study¹, which is now…Levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients: Final long-term non-motor, quality of life and safety results from the GLORIA registry
Objective: To evaluate the tolerability and effect of levodopa-carbidopa intestinal gel (LCIG, designated in the US as carbidopa-levodopa enteral suspension) on non-motor symptoms (NMS), quality…Long-term safety of levodopa-carbidopa intestinal gel from an ongoing, open-label, phase 3 continued access to treatment study in advanced Parkinson’s disease patients
Objective: To assess the safety and tolerability of levodopa-carbidopa intestinal gel (LCIG, designated in the United States as carbidopa-levodopa enteral suspension) in advanced Parkinson's disease…
- « Previous Page
- 1
- …
- 8
- 9
- 10